...
首页> 外文期刊>Vaccine >National Institute of Allergy and Infectious Diseases workshop report: 'Chlamydia vaccines: The way forward'
【24h】

National Institute of Allergy and Infectious Diseases workshop report: 'Chlamydia vaccines: The way forward'

机译:国家过敏和传染病研究所研讨会报告:“衣原体疫苗:前进的方式”

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Chlamydia trachomatis (Ct), an intracellular pathogen, is the most common bacterial sexually transmitted infection. In addition to acute cervicitis and urethritis, Ct can lead to serious sequelae of significant public health burden including pelvic inflammatory disease (PID) and infertility. Ct control efforts have not resulted in desired outcomes such as reduced incidence and reinfection, and this highlights the need for the development of an effective Ct vaccine. To this end, NIAID organized a workshop to consider the current status of Ct vaccine research and address critical questions in Ct vaccine design and clinical testing. Topics included the goal(s) of a vaccine and the feasibility of achieving these goals, animal models of infection including mouse and nonhuman primate (NHP) models, and correlates of protection to guide vaccine design. Decades of research have provided both whole cell-based and subunit vaccine candidates for development. At least one is currently in clinical development and efforts now need to be directed toward further development of the most attractive candidates. Overall, the discussions and presentations from the workshop highlighted optimism about the current status of Ct vaccine research and detailed the remaining gaps and questions needed to move vaccines forward. (C) 2017 Elsevier Ltd. All rights reserved.
机译:衣原体衣原体(CT),一种细胞内病原体,是最常见的细菌性传播感染。除急性宫颈炎和尿道炎外,CT还可以导致严重的公共卫生负担后遗症,包括盆腔炎(PID)和不孕症。 CT控制努力没有导致所需的结果,如发病率和再感染,这突出了对有效CT疫苗的发展的需要。为此,NIAID组织了一个研讨会,以考虑CT疫苗研究的当前状态,并解决CT疫苗设计和临床测试中的关键问题。主题包括疫苗的目标和实现这些目标的可行性,感染动物的动物模型,包括小鼠和非人类灵长类动物(NHP)模型,以及引导疫苗设计的保护相关。几十年的研究提供了整个细胞和亚基疫苗候选人的发展。目前至少有一个是临床发展,现在需要努力进一步发展最具吸引力的候选人。总体而言,研讨会的讨论和演示突出显示了关于CT疫苗研究的当前状态的乐观情绪,并详细说明了向前移动疫苗所需的剩余差距和问题。 (c)2017 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号